Apolipoprotein E (APOE) Peptid
APOE
Reaktivität: Säugetier
Wirt: Synthetic
BP, IHC, WB
-
- Target Alle APOE Produkte
- APOE (Apolipoprotein E (APOE))
- Protein-Typ
- Synthetic
- Spezies
- Säugetier
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
- Sequenz
- KVLWAALLVT FLAGCQAKVE QAVETEPEPE LRQQTEWQSG QRWELALGRF
- Produktmerkmale
-
A synthetic peptide for use as a blocking control in assays to test for specificity of APOE antibody,
Alternative Names: ApoE control peptide, ApoE antibody Blocking Peptide, Anti-ApoE Blocking Peptide, Apolipoprotein E Blocking Peptide, AD2 Blocking Peptide, MGC1571 Blocking Peptide, apoprotein Blocking Peptide
-
Apolipoprotein E (APOE) peptide
APOE Reaktivität: Human Wirt: Synthetic BP, Imm
-
- Applikationshinweise
- Optimal conditions should be determined by the investigator
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handhabung
- Avoid repeated freeze/thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20 °C long term.
-
- Target
- APOE (Apolipoprotein E (APOE))
- Hintergrund
- Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.
- Molekulargewicht
- 34 kDa
-
Sie sind hier:
